Select Page

Israeli medical device startup Vectorious Medical Technology, developer of an innovative miniature implant for left-atrial cardio-vascular monitoring of congestive heart failure (CHF) patients, has raised a $5 million funding round. Investors in the funding round included RAD BioMed and private investors including Zohar Gilon, Gur Muntzer and the Cleveland Clinic’s Global Cardiovascular Innovation Center (GCIC). Vectorious was founded in 2011 by its CEO Oren Goldstein, within the RAD Biomed Accelerator. Goldshtein has served in both managerial and engineering positions in startups and mid-sized companies in the fields of semiconductors and telecommunication. He served as R&D project manager at CopperGate Communication acquired by Sigma Designs), project manager at Amimon Ltd. and system architect at Metalink Ltd. He received a B.Sc. from the Technion-Israel Institute of Technology and an M.Sc from Tel-Aviv University, both in electrical engineering. The startup’s other co-founders are Ronny Winstein, a specialist in intellectual property management and competitive technology intelligence for medical device technologies, and Dr. Eyal Orion, CEO of Vascular Graft Solutions. Via a simple, minimally-invasive implanted device, easy-to-access data and user-friendly external home-unit, the Vectorious system increases CHF patient quality of life and reduces readmission rates. Its daily push-button readings of patient hemodynamic pressure provide early and accurate physiological indications of cardiac decompensation. Vectorious has developed a novel approach to implantable long term hemodynamic monitoring that leverages state-of-the-art technologies in two areas: direct measurement of left atrial pressure and wireless communications. Use of its monitoring system will take the management of heart failure to a new personalized level, leading potentially to a significant reduction in the number of hospital admissions, re-admissions and procedures associated with Heart Failure (HF) decompensation, one of the world’s most costly and pervasive medical challenges. Hospitalization related to HF is a huge financial burden throughout the developed world. In the US alone, there are over 1.1 million HF-related hospitalizations per year, representing a total of over $30 billion in direct annual costs. Importantly, due to its progressive and unstable nature, approximately 50% of hospitalized HF patients are readmitted within the first 6 months after discharge. The prevalence of HF is expected to rise in the future as a result of an aging population, improved survival of people with ischemic heart disease and more effective HF .treatments .Vectorious’s initial target market is Class III HF patients with previous hospitalizations. Vectorious’ miniature wireless sensory implant is permanently positioned in the left atrium enabling daily “push-button” pressure readings with a wirelessly connected external unit. The external module remotely powers and interrogates the implant, and then communicates the .information automatically to a TeleHealth center. The implant’s simple approach enables a safe and easy fixation at the inter-atrial septum. Its unique design prevents the formation of thrombus and tissue growth on its sensing element. It is designed to be delivered in a standard trans-septal procedure using a 7 French catheter. The implant has a unique, cutting-edge wireless communication and remote power feeding system .as well as a robust design that enables self-calibration. The data provided by the device is analyzed routinely by specially trained HF specialists who use it to detect early warning signs of congestion weeks before they become apparent symptomatically. This gives the physician ample time to adjust drug doses before the patient’s .condition deteriorates further Vectorious’ sensory implant will be initially commercialized for HF symptomatic patients who have previously required hospitalization for heart failure. Leveraging success with this population, Vectorious will then begin commercializing the device for use in asymptomatic patients.]]>